<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358864</url>
  </required_header>
  <id_info>
    <org_study_id>1220.7</org_study_id>
    <secondary_id>2010-021715-17</secondary_id>
    <nct_id>NCT01358864</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)</brief_title>
  <official_title>A Phase III, Randomised, Double-blind and Placebo Controlled Study of Once Daily BI 201335, 240 mg for 12 or 24 Weeks in Combination With Pegylated interferon-a (PegIFNa) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN/RBV Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12 or
      24 weeks in combination with PegIFN/RBV given for 48 weeks as compared to PegIFN/RBV alone in
      chronic GT-1 hepatitis C virus infected patients who failed a prior PegIFN/RBV treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virological Response 12 Weeks Post Treatment (SVR12)</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>Percentage of participants with sustained virological response (SVR12) 12 weeks post treatment defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level &lt;25 IU/mL (undetected) 12 weeks after the originally planned treatment duration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological Response After 24 Weeks of Treatment Discontinuation (SVR24)</measure>
    <time_frame>24 weeks post treatment, up to 72 weeks</time_frame>
    <description>Percentage of participants with virological response after 24 weeks of treatment discontinuation (SVR24) defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level &lt;25 IU/mL (undetected) 24 weeks after the originally planned treatment duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Treatment Success (ETS)</measure>
    <time_frame>Week 4 and Week 8</time_frame>
    <description>Percentage of participants with early Treatment Success (ETS) defined as a plasma HCV RNA level &lt;25 IU/mL (undetected or detected) at Week 4 and &lt;25 IU/mL (undetected) at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=NO</measure>
    <time_frame>End of treatment, up to 48 weeks</time_frame>
    <description>The number of participants with alanine aminotransferase (ALT) in normal range at the end of treatment (EoT) when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=YES</measure>
    <time_frame>End of treatment, up to 48 weeks</time_frame>
    <description>The number of participants with alanine aminotransferase (ALT) in normal range at the end of treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=NO</measure>
    <time_frame>End of treatment, up to 48 weeks</time_frame>
    <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=YES</measure>
    <time_frame>End of treatment, up to 48 weeks</time_frame>
    <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment (EoT) when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, When SVR12=NO</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>The number of participants with alanine aminotransferase (ALT) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, SVR12=YES</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>The number of participants with alanine aminotransferase (ALT) in normal range post treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, When SVR12=NO</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>The number of participants with aspartate aminotransferase (AST) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, SVR12=YES</measure>
    <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
    <description>The number of participants with aspartate aminotransferase (AST) in normal range post treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">678</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Placebo/PegIFN/RBV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient to receive two capsules identical to those containing BI201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI201335 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive two capsules containing BI 201335 once a day for 12 weeks and PegIFN/RBV for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI201335 24 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive two capsules containing BI 201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>BI 201335 once a day (QD) for 24 weeks</description>
    <arm_group_label>BI201335 24 weeks</arm_group_label>
    <arm_group_label>BI201335 12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon-alpha (IFN)</intervention_name>
    <description>Pegylated Interferon-alpha for 48 weeks</description>
    <arm_group_label>Placebo/PegIFN/RBV</arm_group_label>
    <arm_group_label>BI201335 12 weeks</arm_group_label>
    <arm_group_label>BI201335 24 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Ribavirin (RBV) for 24 or 48 weeks</description>
    <arm_group_label>BI201335 24 weeks</arm_group_label>
    <arm_group_label>Placebo/PegIFN/RBV</arm_group_label>
    <arm_group_label>BI201335 12 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to BI201335 for 24 weeks</description>
    <arm_group_label>Placebo/PegIFN/RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Chronic hepatitis C genotype 1 infection, diagnosed at least 6 months prior to
             screening

          2. Confirmed prior virological failure with an approved dose of PegIFN/RBV

          3. Age 18 to 70 years,

          4. HCV RNA (RiboNucleic Acid) = 1,000 IU/mL at screening,

        Exclusion criteria:

          1. HCV infection of mixed genotype; Hepatitis B Virus (HBV) or Human Immunodeficiency
             Virus (HIV) co-infection

          2. Evidence of acute or chronic liver disease due to causes other than chronic HCV
             infection,

          3. Decompensated liver disease, or history of decompensated liver disease,

          4. Body weight &lt; 40 or &gt; 125 kg,

          5. Clinical evidence of significant or unstable cardiovascular disease, chronic pulmonary
             disease, history or evidence of retinopathy or clinically significant ophthalmological
             disorder

          6. Pre-existing psychiatric condition that could interfere with the subject's
             participation in and completion of the study

          7. Laboratory parameters disorders (thalassemia major, sickle cell anemia or G6PD
             deficit)

          8. Hemoglobin &lt; 12 g/dL for women and &lt; 13 g/dL for men

          9. Patients who have been previously treated with at least one dose of any antiviral or
             immunomodulatory drug other than interferon alfa or ribavirin for acute or chronic HCV
             infection including and not restricted to protease or polymerase inhibitors,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1220.7.0091 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0095 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vaiparaiso</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0087 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jette</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.1014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3311 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice Cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3310 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3316 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pessac Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3317 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3315 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rennes Cedex 09</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3318 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3308 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vandoeuvre Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4913 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4918 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Herne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4911 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiba, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gifu, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itabashi-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izunokuni, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamakura, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-gun, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kofu, Yamanashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurashiki, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurume, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsumoto, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsuyama, Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Namegata, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishinomiya, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8125 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ogaki, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omura, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8122 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omuta, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8121 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tanabe, Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toyama,Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8126 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tsu, Mie</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.8104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tsuchiura, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3509 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barreiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3506 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.0034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3411 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3412 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Majadahonda-Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.3407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vigo (Pontevedra)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Chaux-de-Fonds</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.7.4403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2011</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2011</study_first_posted>
  <results_first_submitted>July 3, 2015</results_first_submitted>
  <results_first_submitted_qc>September 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2015</results_first_posted>
  <disposition_first_submitted>April 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 19, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 29, 2014</disposition_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Relapser:Placebo</title>
          <description>Patients who had had a prior relapse, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Relapser:Faldaprevir 12 Weeks</title>
          <description>Patients who had had a prior relapse, received Faldaprevir (BI 201335) 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
        </group>
        <group group_id="P3">
          <title>Relapser:Faldaprevir 24 Weeks</title>
          <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
        </group>
        <group group_id="P4">
          <title>Partial:Placebo</title>
          <description>Patients who had had a prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Partial:Faldaprevir 12 Weeks</title>
          <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Partial:Faldaprevir 24 Weeks</title>
          <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Null:Faldaprevir 12 Weeks</title>
          <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Null:Faldaprevir 24 Weeks</title>
          <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="103"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="57"/>
                <participants group_id="P6" count="55"/>
                <participants group_id="P7" count="146"/>
                <participants group_id="P8" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="87"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="42"/>
                <participants group_id="P7" count="81"/>
                <participants group_id="P8" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="65"/>
                <participants group_id="P8" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="49"/>
                <participants group_id="P8" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS)</population>
      <group_list>
        <group group_id="B1">
          <title>Relapser:Placebo</title>
          <description>Patients who had had a prior relapse, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Relapser:Faldaprevir 12 Weeks</title>
          <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
        </group>
        <group group_id="B3">
          <title>Relapser:Faldaprevir 24 Weeks</title>
          <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
        </group>
        <group group_id="B4">
          <title>Partial:Placebo</title>
          <description>Patients who had had a prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Partial:Faldaprevir 12 Weeks</title>
          <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Partial:Faldaprevir 24 Weeks</title>
          <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Null:Faldaprevir 12 Weeks</title>
          <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Null:Faldaprevir 24 Weeks</title>
          <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="103"/>
            <count group_id="B4" value="29"/>
            <count group_id="B5" value="57"/>
            <count group_id="B6" value="55"/>
            <count group_id="B7" value="145"/>
            <count group_id="B8" value="140"/>
            <count group_id="B9" value="677"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" spread="8.29"/>
                    <measurement group_id="B2" value="53.5" spread="8.57"/>
                    <measurement group_id="B3" value="53.7" spread="8.14"/>
                    <measurement group_id="B4" value="55.7" spread="7.50"/>
                    <measurement group_id="B5" value="52.7" spread="7.90"/>
                    <measurement group_id="B6" value="52.0" spread="10.32"/>
                    <measurement group_id="B7" value="53.2" spread="8.76"/>
                    <measurement group_id="B8" value="53.6" spread="8.13"/>
                    <measurement group_id="B9" value="53.4" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="54"/>
                    <measurement group_id="B8" value="63"/>
                    <measurement group_id="B9" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="91"/>
                    <measurement group_id="B8" value="77"/>
                    <measurement group_id="B9" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Virological Response After 24 Weeks of Treatment Discontinuation (SVR24)</title>
        <description>Percentage of participants with virological response after 24 weeks of treatment discontinuation (SVR24) defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level &lt;25 IU/mL (undetected) 24 weeks after the originally planned treatment duration.</description>
        <time_frame>24 weeks post treatment, up to 72 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Relapser &amp; Partial: Placebo</title>
            <description>Patients who had had a prior relapse or prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relapser &amp; Partial: Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior relapse or prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks (for the partial relapsers the last 24 weeks was only if the patient did not achieve early treatment success (ETS)).</description>
          </group>
          <group group_id="O3">
            <title>Relapser &amp; Partial: Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior relapse or prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks (for the partial relapsers the last 24 weeks was only if the patient did not achieve early treatment success (ETS)).</description>
          </group>
          <group group_id="O4">
            <title>Null:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Null:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Virological Response After 24 Weeks of Treatment Discontinuation (SVR24)</title>
          <description>Percentage of participants with virological response after 24 weeks of treatment discontinuation (SVR24) defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level &lt;25 IU/mL (undetected) 24 weeks after the originally planned treatment duration.</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="145"/>
                <count group_id="O5" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="3.5" upper_limit="17.0"/>
                    <measurement group_id="O2" value="63.5" lower_limit="55.9" upper_limit="71.0"/>
                    <measurement group_id="O3" value="59.5" lower_limit="51.8" upper_limit="67.1"/>
                    <measurement group_id="O4" value="33.8" lower_limit="26.1" upper_limit="41.5"/>
                    <measurement group_id="O5" value="32.9" lower_limit="25.1" upper_limit="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted for genotype and previous response to treatment</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percent difference</param_type>
            <param_value>52.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>42.4</ci_lower_limit>
            <ci_upper_limit>63.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted for genotype and previous response to treatment</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percent difference</param_type>
            <param_value>48.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>38.2</ci_lower_limit>
            <ci_upper_limit>58.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted percent difference</param_type>
            <param_value>4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>14.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted percent difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.9</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison is based on the Null:Faldaprevir 12 weeks vs historical rate of 20%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Normal approximation</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison is based on the Null:Faldaprevir 24 weeks vs historical rate of 20%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Normal approximation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Treatment Success (ETS)</title>
        <description>Percentage of participants with early Treatment Success (ETS) defined as a plasma HCV RNA level &lt;25 IU/mL (undetected or detected) at Week 4 and &lt;25 IU/mL (undetected) at Week 8.</description>
        <time_frame>Week 4 and Week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Relapser:Placebo</title>
            <description>Patients who had had a prior relapse, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relapser:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Relapser:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O4">
            <title>Partial:Placebo</title>
            <description>Patients who had had a prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Partial:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Partial:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Null:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Null:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Early Treatment Success (ETS)</title>
          <description>Percentage of participants with early Treatment Success (ETS) defined as a plasma HCV RNA level &lt;25 IU/mL (undetected or detected) at Week 4 and &lt;25 IU/mL (undetected) at Week 8.</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="145"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="85.9"/>
                    <measurement group_id="O3" value="87.4"/>
                    <measurement group_id="O4" value="3.4"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="76.4"/>
                    <measurement group_id="O7" value="58.6"/>
                    <measurement group_id="O8" value="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sustained Virological Response 12 Weeks Post Treatment (SVR12)</title>
        <description>Percentage of participants with sustained virological response (SVR12) 12 weeks post treatment defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level &lt;25 IU/mL (undetected) 12 weeks after the originally planned treatment duration.</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Relapser &amp; Partial: Placebo</title>
            <description>Patients who had had a prior relapse or prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relapser &amp; Partial: Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior relapse or prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks (for the partial relapsers the last 24 weeks was only if the patient did not achieve early treatment success (ETS)).</description>
          </group>
          <group group_id="O3">
            <title>Relapser &amp; Partial: Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior relapse or prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks (for the partial relapsers the last 24 weeks was only if the patient did not achieve early treatment success (ETS)).</description>
          </group>
          <group group_id="O4">
            <title>Null:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Null:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virological Response 12 Weeks Post Treatment (SVR12)</title>
          <description>Percentage of participants with sustained virological response (SVR12) 12 weeks post treatment defined as plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level &lt;25 IU/mL (undetected) 12 weeks after the originally planned treatment duration.</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="145"/>
                <count group_id="O5" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="3.5" upper_limit="17.0"/>
                    <measurement group_id="O2" value="65.4" lower_limit="57.9" upper_limit="72.9"/>
                    <measurement group_id="O3" value="61.4" lower_limit="53.8" upper_limit="69.0"/>
                    <measurement group_id="O4" value="33.8" lower_limit="26.1" upper_limit="41.5"/>
                    <measurement group_id="O5" value="32.9" lower_limit="25.1" upper_limit="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted for genotype and previous response to treatment</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percent difference</param_type>
            <param_value>54.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44.4</ci_lower_limit>
            <ci_upper_limit>65.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted for genotype and previous response to treatment</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Adjusted percent difference</param_type>
            <param_value>50.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>40.1</ci_lower_limit>
            <ci_upper_limit>60.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted percent difference</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.8</ci_lower_limit>
            <ci_upper_limit>14.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted percent difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.9</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison is based on the Null:Faldaprevir 12 weeks vs historical rate of 20%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Normal approximation</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison is based on the Null:Faldaprevir 24 weeks vs historical rate of 20%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Normal approximation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=NO</title>
        <description>The number of participants with alanine aminotransferase (ALT) in normal range at the end of treatment (EoT) when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
        <time_frame>End of treatment, up to 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Relapser:Placebo</title>
            <description>Patients who had had a prior relapse, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relapser:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Relapser:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O4">
            <title>Partial:Placebo</title>
            <description>Patients who had had a prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Partial:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Partial:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Null:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Null:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=NO</title>
          <description>The number of participants with alanine aminotransferase (ALT) in normal range at the end of treatment (EoT) when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="145"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12=NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="96"/>
                    <measurement group_id="O8" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL normal to EoT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL elevated to EoT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="34"/>
                    <measurement group_id="O8" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No EoT data available for ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=YES</title>
        <description>The number of participants with alanine aminotransferase (ALT) in normal range at the end of treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
        <time_frame>End of treatment, up to 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Relapser:Placebo</title>
            <description>Patients who had had a prior relapse, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relapser:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Relapser:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O4">
            <title>Partial:Placebo</title>
            <description>Patients who had had a prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Partial:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Partial:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Null:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Null:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=YES</title>
          <description>The number of participants with alanine aminotransferase (ALT) in normal range at the end of treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="145"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12=YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="49"/>
                    <measurement group_id="O8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL normal to EoT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL elevated to EoT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=NO</title>
        <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
        <time_frame>End of treatment, up to 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Relapser:Placebo</title>
            <description>Patients who had had a prior relapse, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relapser:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Relapser:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O4">
            <title>Partial:Placebo</title>
            <description>Patients who had had a prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Partial:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Partial:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Null:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Null:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=NO</title>
          <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="145"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12=NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="96"/>
                    <measurement group_id="O8" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL normal to EoT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL elevated to EoT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=YES</title>
        <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment (EoT) when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
        <time_frame>End of treatment, up to 48 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Relapser:Placebo</title>
            <description>Patients who had had a prior relapse, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relapser:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Relapser:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O4">
            <title>Partial:Placebo</title>
            <description>Patients who had had a prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Partial:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Partial:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Null:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Null:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=YES</title>
          <description>The number of participants with aspartate aminotransferase (AST) in normal range at the end of treatment (EoT) when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="145"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12=YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="49"/>
                    <measurement group_id="O8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL normal to EoT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL elevated to EoT normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No EoT data available for AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, When SVR12=NO</title>
        <description>The number of participants with alanine aminotransferase (ALT) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Relapser:Placebo</title>
            <description>Patients who had had a prior relapse, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relapser:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Relapser:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O4">
            <title>Partial:Placebo</title>
            <description>Patients who had had a prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Partial:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Partial:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Null:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Null:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, When SVR12=NO</title>
          <description>The number of participants with alanine aminotransferase (ALT) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="145"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12=NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="96"/>
                    <measurement group_id="O8" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL normal to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL elevated to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No ALT data available at SVR12 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, SVR12=YES</title>
        <description>The number of participants with alanine aminotransferase (ALT) in normal range post treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Relapser:Placebo</title>
            <description>Patients who had had a prior relapse, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relapser:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Relapser:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O4">
            <title>Partial:Placebo</title>
            <description>Patients who had had a prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Partial:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Partial:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Null:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Null:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, SVR12=YES</title>
          <description>The number of participants with alanine aminotransferase (ALT) in normal range post treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="145"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12=YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="49"/>
                    <measurement group_id="O8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL normal to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL elevated to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No ALT data available at SVR12 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, When SVR12=NO</title>
        <description>The number of participants with aspartate aminotransferase (AST) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Relapser:Placebo</title>
            <description>Patients who had had a prior relapse, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relapser:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Relapser:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O4">
            <title>Partial:Placebo</title>
            <description>Patients who had had a prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Partial:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Partial:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Null:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Null:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, When SVR12=NO</title>
          <description>The number of participants with aspartate aminotransferase (AST) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment. BL=baseline</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="145"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12=NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="96"/>
                    <measurement group_id="O8" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL normal to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL elevated to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No AST data available at SVR12 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, SVR12=YES</title>
        <description>The number of participants with aspartate aminotransferase (AST) in normal range post treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
        <time_frame>12 weeks post treatment, up to 60 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Relapser:Placebo</title>
            <description>Patients who had had a prior relapse, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Relapser:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O3">
            <title>Relapser:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior relapse, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. At week 24, if the patients did not achieve early treatment success (ETS) the patients received an additional 24 weeks of PegIFN/RBV alone.</description>
          </group>
          <group group_id="O4">
            <title>Partial:Placebo</title>
            <description>Patients who had had a prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV (Pegylated interferon alpha-2a/Ribavirin) administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Partial:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Partial:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Null:Faldaprevir 12 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Null:Faldaprevir 24 Weeks</title>
            <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, SVR12=YES</title>
          <description>The number of participants with aspartate aminotransferase (AST) in normal range post treatment when patients have sustained virological response 12 weeks post treatment. BL=baseline</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="57"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="145"/>
                <count group_id="O8" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12=YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="49"/>
                    <measurement group_id="O8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL normal to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL elevated to SVR12 normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No AST data available at SVR12 visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the course of the study (48 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Relapser &amp; Partial: Placebo</title>
          <description>Patients who had had a prior relapse or prior partial response, received 2 soft gelatin capsules identical to those containing Faldaprevir once daily (orally) and PegIFN/RBV administered by injection, for 24 weeks, followed by PegIFN/RBV for 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Relapser &amp; Partial: Faldaprevir 12 Weeks</title>
          <description>Patients who had had a prior relapse or prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks (for the partial relapsers the last 24 weeks was only if the patient did not achieve early treatment success (ETS)).</description>
        </group>
        <group group_id="E3">
          <title>Relapser &amp; Partial: Faldaprevir 24 Weeks</title>
          <description>Patients who had had a prior relapse or prior partial response, received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks (for the partial relapsers the last 24 weeks was only if the patient did not achieve early treatment success (ETS)).</description>
        </group>
        <group group_id="E4">
          <title>Null:Faldaprevir 12 Weeks</title>
          <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 12 weeks, followed by placebo once daily combined with PegIFN/RBV for 12 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Null:Faldaprevir 24 Weeks</title>
          <description>Patients who had had a prior null response received Faldaprevir 240mg once daily, in the form of 2 soft gelatin capsules administered orally, combined with PegIFN/RBV, administered by injection, for 24 weeks. Followed by PegIFN/RBV alone for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Keratosis follicular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Oral lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hepatorenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>International normalised ratio abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Psychiatric decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="156" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="142" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="139" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="88" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="75" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="63" subjects_at_risk="140"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

